Molecular target therapy for synovial sarcoma

Future Oncology

Volumn 1, Issue 6, 2005, Pages 805-812

  Fukukawa, Chikako ^a   Nakamura, Yusuke ^a   Katagiri, Toyomasa ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

antibody therapy; cDNA microarray; soft tissue tumor; synovial sarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

CONNECTIVE TISSUE TUMOR; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SARCOMA, SYNOVIAL; TUMOR MARKERS, BIOLOGICAL;

EID: 34047155601     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.1.6.805     Document Type: Review

References (54)

1. Weiss SW, Goldblum JR: Enzinger and Weisss Soft Tissue Tumor. 4th Edition. MO, USA (2001).
2. Ochi N, Uozumi M, Doi K et al.: Synovial sarcoma of the neck. ORL. J. Otorhinolaryngol. Relat. Spec. 66(1), 42-45 (2004).
3. Coindre JM, Pelmus M, Hostein I et al.: Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer 98(12), 2700-2707 (2003).
4. McGilbray TT, Schulz TK: Clinical picture: primary cardiac synovial sarcoma. Lancet Oncol. 4(5), 283 (2003).
5. Hosono T, Hironaka M, Kobayashi A et al.: Primary pulmonary synovial sarcoma confirmed by molecular detection of SYT-SSX1 fusion gene transcripts: a case report and review of the literature. Jpn J. Clin. Oncol. 35(5), 274-279 (2005).
6. Habu S, Okamoto E, Toyosaka A, Nakai Y, Takeuchi M: Synovial sarcoma of the esophagus: report of a case. Surg. Today. 28(4), 401-404 (1998).
7. Hiraga H, Nojima T, Isu K et al.: Histological and molecular evidence of synovial sarcoma of bone. A case report. J. Bone Joint Surg. Am. 81(4), 558-563 (1999).
8. Szuhai K, Knijnenburg J, Ijszenga M et al.: Multicolor fluorescence in situ hybridization analysis of a synovial sarcoma of the larynx with a t(X;18)(p11.2;q11.2) and trisomies 2 and 8. Cancer Genet. Cytogenet. 153(1), 48-52 (2004).
9. Shannon BA, Murch A, Cohen RJ: Primary renal synovial sarcoma confirmed by cytogenetic analysis: a lesion distinct from sarcomatoid renal cell carcinoma. Arch. Pathol. Lab. Med. 129(2), 238-240 (2005).
10. Williams DH, Hua VN, Chowdhry AA et al.: Synovial sarcoma of the prostate. J. Urol. 171(6 Pt 1), 2376 (2004).
11. Smith ME, Fisher C, Wilkinson LS, Edwards JC: Synovial sarcoma lack synovial differentiation. Histopathology 26(3), 279-281 (1995).
12. Ghadially FN: Is synovial sarcoma a carcinosarcoma of connective tissue? Ultrastruct. Pathol. 11(23), 147-151 (1987).
13. Limon J, Dal Cin P, Sandberg AA: Translocations involving the X chromosome in solid tumors: presentation of two sarcomas with t(X;18)(q13;p11). Cancer Genet. Cytogenet. 23(1), 87-91 (1986).
14. Turc-Carel C, Dal Cin P, Limon J, Li F, Sandberg AA: Translocation X;18 in synovial sarcoma. Cancer Genet. Cytogenet. 23(1), 93 (1986).
15. Clark J, Rocques PJ, Crew AJ et al.: Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nature Genet. 7(4), 502-508 (1994).
16. Tomescu O, Barr FG: Chromosomal translocations in sarcomas: prospects for therapy. Trends Mol. Med. 7(12), 554-559 (2001).
17. Kawai A, Woodruff J, Healey JH et al.: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med. 338(3), 153-160 (1998).
18. Agus V, Tamborini E, Mezzelani A, Pierotti MA, Pilotti S: Re: a novel fusion gene, SYT-SSX4, in synovial sarcoma. J. Natl Cancer Inst. 93(17), 1347-1349 (2001).
19. Tsuji S, Hisaoka M, Morimitsu Y et al.: Detection of SYT-SSX fusion transcripts in synovial sarcoma by reverse transcriptionpolymerase chain reaction using archival paraffin-embedded tissues. Am. J. Pathol. 153(6), 1807-1812 (1998).
20. Shipley J, Crew J, Birdsall S et al.: Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma. Am. J. Pathol. 148(2), 559-567 (1996).
21. Nagao K, Ito H, Yoshida H: Chromosomal translocation t(X;18) in human synovial sarcomas analyzed by fluorescence in situ hybridization using paraffin-embedded tissue. Am. J. Pathol. 148(2), 601-609 (1996).
22. Brett D, Whitehouse S, Antonson P, Shipley J, Cooper C, Goodwin G: The SYT protein involved in the t(X;18) synovial sarcoma translocation is a transcriptional activator localised in nuclear bodies. Hum. Mol. Genet. 6(9), 1559-1564 (1997).
23. Lim FL, Soulez M, Koczan D, Thiesen HJ, Knight JC: A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17(15), 2013-2018 (1998).
24. Soulez M, Saurin AJ, Freemont PS, Knight JC: SSX and the synovial-sarcomaspecific chimaeric protein SYT-SSX colocalize with the human Polycomb group complex. Oncogene 18(17), 2739-2746 (1999).
25. dos Santos NR, de Bruijn DR, van Kessel AG: Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer. 30(1), 1-14 (2001)
26. Ladanyi M: Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 20(40), 5755-5762 (2001).
27. dos Santos NR, de Bruijn DR, Balemans M et al.: Nuclear localization of SYT, SSX and the synovial sarcoma-associated SYT-SSX fusion proteins. Hum. Mol. Genet. 6(9), 1549-1558 (1997).
28. Kato H, Tjernberg A, Zhang W et al.: SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones. J. Biol. Chem. 277(7), 5498-5505 (2002).
29. Nagai M, Tanaka S, Tsuda M et al.: Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha. Proc. Natl Acad. Sci. USA 98(7), 3843-3848 (2001).
30. Xie Y, Tornkvist M, Aalto Y et al.: Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene. Oncogene 22(48), 7628-7631 (2003).
31. Chu PG, Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology 40(5), 403-439 (2002).
32. Pelmus M, Guillou L, Hostein I et al.: Monophasic fibrous and poorly differentiated synovial sarcoma: immunohistochemical reassessment of 60 t(X;18)(SYT-SSX)-positive cases. Am. J. Surg. Pathol. 26(11), 1434-1440 (2002).
33. Szymanska J, Serra M, Skytting B et al.: Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. Genes Chromosomes Cancer 23(3), 213-219 (1998).
34. Meltzer PS: Spotting the target: microarrays for disease gene discovery. Curr. Opin. Genet. Dev. 11(3), 258-263 (2001).
35. Allander SV, Illei PB, Chen Y et al.: Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am. J. Pathol. 161(5), 1587-1595 (2002).
36. Nagayama S, Katagiri T, Tsunoda T et al.: Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62(20), 5859-5866 (2002).
37. Nielsen TO, West RB, Linn SC et al.: Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359(9314), 1301-1307 (2002).
38. Segal NH, Pavlidis P, Antonescu CR et al.: Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. Am. J. Pathol. 163(2), 691-700 (2003).
39. Ishibe T, Nakayama T, Okamoto T et al.: Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin. Cancer Res. 11(7), 2702-2712 (2005).
40. Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y: Identification of PDZK4, a novel human gene with PDZ domains, that is upregulated in synovial sarcomas. Oncogene 23(32), 5551-5557 (2004).
41. Lewis JJ, Antonescu CR, Leung DH et al.: Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J. Clin. Oncol. 18(10), 2087-2094 (2000).
42. Worley BS, van den Broeke LT, Goletz TJ et al.: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 61(18), 6868-6875 (2001).
43. Sato Y, Nabeta Y, Tsukahara T et al.: Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLAA24(+) patients with synovial sarcoma. J. Immunol. 169(3), 1611-1618 (2002).
44. Kawaguchi S, Wada T, Ida K et al.: Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J. Transl. Med. 3(1), 1 (2005).
45. Koike J, Takagi A, Miwa T et al.: Molecular cloning of Frizzled-10, a novel member of the Frizzled gene family. Biochem. Biophys. Res. Commun. 262(1), 39-43 (1999).
46. Nagayama S, Fukukawa C, Katagiri T et al.: Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene 24, 6201-6212 (2005).
47. Terasaki H, Saitoh T, Shiokawa K, Katoh M: Frizzled-10, upregulated in primary colorectal cancer, is a positive regulator of the WNT- a-catenin-TCF signaling pathway. Int. J. Mol. Med. 9(2), 107-112 (2002).
48. Kirikoshi H, Sekihara H, Katoh M: Expression profiles of 10 members of Frizzled gene family in human gastric cancer. Int. J. Oncol. 19(4), 767-771 (2001).
49. Baselga J: Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61(Suppl. 2), 14-21 (2001).
50. Maloney DG, Grillo-Lopez AJ, White CA et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma. Blood 90(6), 2188-2195 (1997).
51. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an antiVEGF antibody for treating cancer. Nature Rev. Drug Discov. 3(5), 391-400 (2004).
52. Katsumata M, Okudaira T, Samanta A et al.: Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nature Med. 1(7), 644-648 (1995).
53. van Der Velden VH, te Marvelde JG, Hoogeveen PG et al.: Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97(10), 3197-3204 (2001).
54. Wiseman GA, Witzig TE: Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkins lymphoma. Cancer Biother. Radiopharm. 20(2), 185-188 (2005).